|97.16||-2.85||-2.85%||Vol 314.34K||1Y Perf 17.34%|
|Oct 4th, 2023 16:00 DELAYED|
|- -%||- -|
|Target Price||100.50||Analyst Rating||Moderate Buy 2.00|
|Potential %||3.92||Finscreener Ranking||★ 42.09|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 41.66|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★+ 39.97|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★+ 42.18|
|Price Range Ratio 52W %||38.69||Earnings Rating||Neutral|
|Market Cap||2.99B||Earnings Date||25th Oct 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||25th Oct 2023|
|Estimated EPS Next Report||0.83|
|EPS Growth Next 5 Years %||27.90|
|Avg. Weekly Volume||362.56K|
|Avg. Monthly Volume||321.10K|
|Avg. Quarterly Volume||336.79K|
Conmed Corp. - Ordinary Shares (NASDAQ: CNMD) stock closed at 100.01 per share at the end of the most recent trading day (a 0.69% change compared to the prior day closing price) with a volume of 444.39K shares and market capitalization of 2.99B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 3400 people. Conmed Corp. - Ordinary Shares CEO is Curt R. Hartman.
The one-year performance of Conmed Corp. - Ordinary Shares stock is 17.34%, while year-to-date (YTD) performance is 12.83%. CNMD stock has a five-year performance of 31.47%. Its 52-week range is between 71.09 and 138.47, which gives CNMD stock a 52-week price range ratio of 38.69%
Conmed Corp. - Ordinary Shares currently has a PE ratio of -31.70, a price-to-book (PB) ratio of 3.98, a price-to-sale (PS) ratio of 3.65, a price to cashflow ratio of 36.30, a PEG ratio of -1.14, a ROA of -4.38%, a ROC of -4.13% and a ROE of -12.20%. The company’s profit margin is -13.49%, its EBITDA margin is 6.10%, and its revenue ttm is $794.60 Million , which makes it $26.07 revenue per share.
Of the last four earnings reports from Conmed Corp. - Ordinary Shares, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.83 for the next earnings report. Conmed Corp. - Ordinary Shares’s next earnings report date is 25th Oct 2023.
The consensus rating of Wall Street analysts for Conmed Corp. - Ordinary Shares is Moderate Buy (2), with a target price of $100.5, which is +3.92% compared to the current price. The earnings rating for Conmed Corp. - Ordinary Shares stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Conmed Corp. - Ordinary Shares has a dividend yield of 0.84% with a dividend per share of $0.80 and a payout ratio of 44.00%.
Conmed Corp. - Ordinary Shares has a Sell technical analysis rating based on Technical Indicators (ADX : 8.65, ATR14 : 2.70, CCI20 : -91.05, Chaikin Money Flow : -0.20, MACD : -3.10, Money Flow Index : 34.64, ROC : -7.12, RSI : 36.66, STOCH (14,3) : 23.00, STOCH RSI : 0.88, UO : 41.64, Williams %R : -77.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Conmed Corp. - Ordinary Shares in the last 12-months were: Berge Terence (Option Excercise at a value of $1 040 927), Berge Terence (Sold 13 300 shares of value $1 685 415 ), Brent Lalomia (Option Excercise at a value of $0), Bronson David (Option Excercise at a value of $0), Cohen Heather (Option Excercise at a value of $164 650), Concannon Brian (Option Excercise at a value of $0), Concannon Brian (Sold 2 884 shares of value $363 756 ), Council Laverne (Option Excercise at a value of $0), Curt R. Hartman (Sold 11 000 shares of value $1 064 079 ), Daniel S. .Jonas (Option Excercise at a value of $1 694 484), Daniel S. .Jonas (Sold 20 400 shares of value $2 261 193 ), Daniel S. Jonas (Option Excercise at a value of $717 584), Daniel S. Jonas (Sold 10 400 shares of value $1 000 104 ), Farkas Charles (Option Excercise at a value of $0), Garner Todd (Option Excercise at a value of $1 746 045), Garner Todd (Sold 34 500 shares of value $3 129 803 ), Jaclyn Peterson (Option Excercise at a value of $0), John D. Ferrell (Option Excercise at a value of $71 281), John D. Ferrell (Sold 1 700 shares of value $224 077 ), Lalomia Brent (Option Excercise at a value of $0), Lande Jerome (Option Excercise at a value of $0), Pelletier Johonna (Option Excercise at a value of $1 494 103), Pelletier Johonna (Sold 18 617 shares of value $2 353 831 ), Peters Stanley (Sold 0 shares of value $-419 300 ), Peters Stanley (Sold 10 000 shares of value $1 230 530 ), Peterson Jaclyn (Sold 0 shares of value $0 ), Schwarzentraub Barbara (Option Excercise at a value of $0), Shagory Peter (Option Excercise at a value of $346 753), Shagory Peter (Sold 2 442 shares of value $312 576 ), Todd W. Garner (Sold 0 shares of value $-1 746 045 ), Todd W. Garner (Sold 34 500 shares of value $3 129 834 )
Mon, 24 Jul 2023 12:20 GMT Analysts Offer Insights on Healthcare Companies: Conmed (CNMD) and Roche Holding AG (OtherRHHVF)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.